伊马替尼和美特福林在老鼠中的药理动力相互作用
Naling Fan1, Liying Du1, Teng Guo1
1Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of clinical Pharmacy, Health Road, Chang'an District, Shijiazhuang City, Hebei Province, People's Republic of China.
European journal of drug metabolism and pharmacokinetics
|December 23, 2023
概括
甲福明在大鼠中显著降低了意马替尼和N-甲基意马替尼的水平,影响了药物的疗效. 由于潜在的药物相互作用,建议在同时服用这些药物时谨慎使用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物代谢和药理动力学
- 毒理学 毒理学 毒理学
背景情况:
- 伊马替尼布是一种至关重要的药物,主要通过肝脏输送体 (如OCT1.1) 代谢和排出.
- 伊马替尼布患者通常使用的甲胺也是OCT1的基质,这表明药物相互作用的潜力.
- 这些相互作用可能会危及伊马替尼的临床有效性.
研究的目的:
- 在大鼠模型中研究甲胺对伊马替尼布及其活性代谢物N-desmethyl imatinib的药理动力学影响.
- 评估伊马替尼布和美特福林之间潜在的药物相互作用.
主要方法:
- 20只Sprague-Dawley大鼠被分为对照组和实验组.
- 对照组服用伊马替尼布 (30毫克/公斤) 口服14天.
- 实验组在14天内口服伊马替尼布 (30毫克/千克) 和甲胺 (200毫克/千克) 的同时使用.
- 使用超高性能液态染色体质谱分析了意马替尼和N-desmethyl imatinib的血度.
主要成果:
- 单剂量同时使用导致血度-时间曲线 (AUC0-24) 和伊马替尼的最大度 (Cmax) 下面的区域显著减少,并降低了N-desmethyl imatinib的MRT和Cmax.
- 与对照组相比,在14天内多剂量同时使用导致意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利意大利
- 这些变化具有统计学意义 (P<0.05).
结论:
- 甲福明显著改变了伊马替尼布及其活性代谢物N-desmethyl imatinib的药理学参数.
- 这些发现表明甲福明和伊马替尼布之间存在临床相关的药物相互作用.
- 医疗保健提供者在与伊马替尼布同时处方甲型胺时应谨慎行事,以确保治疗疗效和患者安全.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
Dipeptidyl Peptidase 4 Inhibitors
189
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
189
Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
Factors Affecting Drug Biotransformation: Biological
153
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
153
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
179
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
179
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
249
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
249


